Achaogen: Cipla arm acquires anti-infective Zemdri from Achaogen to treat cUTI

Cipla USA has acquired worldwide rights of Zemdri, excluding Greater China, with its allied assets and limited liabilities, Cipla said in a late-night regulatory filing on Wednesday. New Delhi: Drug firm Cipla has said its arm Cipla USA Inc has acquired prescription drug Zemdri, used for the treatment of complicated urinary tract infections, from Achaogen Inc. Cipla USA has acquired worldwide rights of Zemdri, excluding Greater China, with its allied assets and limited liabilities, Cipla said in a late-night regulatory filing on Wednesday. "The acquisition of Zemdri deepens our pipeline